Literature DB >> 29315816

Uncovering the potential of CD44v/SYNE1/miR34a axis in salivary fluids of oral cancer patients.

Kavan Shah1, Shanaya Patel1, Bansri Modi1, Franky Shah1, Rakesh Rawal2.   

Abstract

OBJECTIVES: Late-stage diagnosis is one of the major confounders for poor prognosis of patients with oral cancer owing to lack of a biomarker to diagnose this disease at an early stage. Moreover, till date, invasive biopsies are the only option to assess disease occurrence and progression in this malignancy. Thus, this study aims to identify and assess potential salivary markers in OSCC patients in order to open newer avenues in the field of non-invasive biopsies.
METHODOLOGY: Bioinformatic-based analysis was performed to identify potential biomarkers that could be assessed in OSCC patients. The expression patterns of CD44v and its genetic and epigenetic modulators were assessed in saliva of OSCC patients, leukoplakia, and controls using real-time and methylation-specific PCR. Statistical analysis was conducted to understand the significance of these markers in terms of their clinical relevance.
RESULTS: CD44v/SYNE1/miR34a axis was identified using bioinformatic analysis, and the expression profile of these markers was assessed in saliva of OSCC patients. CD44v6 and CD44v10 demonstrated a significantly increased expression, whereas SYNE1 and miR34a depicted a significantly decreased expression in OSCC patients. Statistical analysis suggested a probable role of CD44v6, SYNE1, and miR34a in early stages of the malignancy, whereas a strong association was observed between CD44v6, CD44v10, and miR34a expression with locoregional aggressiveness and histopathological conditions.
CONCLUSION: Collectively, these findings suggested a plausible role of CD44v/SYNE1/miR34a axis as non-invasive salivary biomarkers to diagnose this disease at an early stage and predict the early onset of metastasis.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cell-free RNA; early risk predictors; liquid biopsy; oral cancer; salivary biomarkers

Mesh:

Substances:

Year:  2018        PMID: 29315816     DOI: 10.1111/jop.12678

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  9 in total

1.  Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2019-08-19       Impact factor: 3.356

2.  Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Authors:  Xuefei Yan; Beibei Tang; Biao Chen; Yongli Shan; Huajun Yang; Elizabeth Iorns; Rachel Tsui; Alexandria Denis; Nicole Perfito; Timothy M Errington
Journal:  Elife       Date:  2019-03-12       Impact factor: 8.140

3.  The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery.

Authors:  Hanxue Sun; Sanyukta Rana; Zhe Wang; Kun Zhao; Martina Schnölzer; Jan Provaznik; Thilo Hackert; Qingjie Lv; Margot Zöller
Journal:  J Oncol       Date:  2019-08-07       Impact factor: 4.375

Review 4.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

5.  SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients.

Authors:  Pengju Li; Jeifei Xiao; Bangfen Zhou; Jinhuan Wei; Junhang Luo; Wei Chen
Journal:  Aging (Albany NY)       Date:  2020-10-08       Impact factor: 5.682

6.  SPDEF suppresses head and neck squamous cell carcinoma progression by transcriptionally activating NR4A1.

Authors:  Yanting Wang; Xianyue Ren; Weiyu Li; Ruoyan Cao; Suyang Liu; Laibo Jiang; Bin Cheng; Juan Xia
Journal:  Int J Oral Sci       Date:  2021-10-20       Impact factor: 6.344

Review 7.  Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.

Authors:  Giuseppe Gattuso; Salvatore Crimi; Alessandro Lavoro; Roberta Rizzo; Giorgia Musumarra; Simona Gallo; Flavia Facciponte; Sabrina Paratore; Angela Russo; Roberto Bordonaro; Gaetano Isola; Alberto Bianchi; Massimo Libra; Luca Falzone
Journal:  Noncoding RNA       Date:  2022-08-10

8.  Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.

Authors:  Seri Jeong; Yu Jin Park; Woobin Yun; Seung-Tae Lee; Jong Rak Choi; Cheolwon Suh; Jae-Cheol Jo; Hee Jeong Cha; Jee-Yeong Jeong; HeeKyung Chang; Yoon Jin Cha; Hyerim Kim; Min-Jeong Park; Wonkeun Song; Eun-Hae Cho; Eun-Goo Jeong; Junnam Lee; Yongmin Park; Yong Seok Lee; Da Jung Kim; Ho Sup Lee
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

9.  SYNE1 Exonic Variant rs9479297 Contributes to Concurrent Hepatocellular and Transitional Cell Carcinoma Double Primary Cancer.

Authors:  Yu-De Chu; Kwong-Ming Kee; Wey-Ran Lin; Ming-Wei Lai; Sheng-Nan Lu; Wen-Hung Chung; See-Tong Pang; Chau-Ting Yeh
Journal:  Biomedicines       Date:  2021-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.